Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
Ever since the COVID-19 pandemic began to ease, Moderna has weathered a sharp revenue downturn. But a new FDA approval shows that the company's scientific engine is no one trick pony. Moderna's ...
Moderna’s shot is the third RSV vaccine for people 60 and older that’s gotten the green light from the FDA and the first mRNA vaccine among them. It’s the company’s second product to ...
The Food and Drug Administration approved Moderna's vaccine for respiratory syncytial virus. The decision is a win for Moderna, which desperately needs another revenue source amid plunging demand ...
The US Food and Drug Administration has approved another vaccine to help protect older people from respiratory syncytial virus, known as RSV. The shot, made by Moderna and sold under the name of ...
The Food and Drug Administration on Friday approved Moderna’s vaccine to protect older adults against respiratory syncytial virus, or RSV, making this the company’s second licensed product.
Synopsys VC Verification IP (VIP) for ARM® AMBA® AXI™ provides complete protocol support for AXI3™, AXI4™, AXI4-Lite™, AXI4-Stream™, ACE™, ACE-Lite™ , AHB™ and APB™ interfaces. ... Synopsys® VC ...
, opens new tab respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product. Moderna's vaccine was approved for ...
CAMBRIDGE, MA - Moderna , Inc. (NASDAQ:MRNA) has received approval from the U.S. Food and Drug Administration (FDA) for its mRNA respiratory syncytial virus (RSV) vaccine, mRESVIA, to prevent lower ...